Ostatnia aktualizacja :
26/03/2024
Lek cytostatyk   Cisplatin  
Injekcje
Trwałość roztworów Trwałość w mieszaninie Czynnik wpływający na trwałość Zgodność Sposób podania Bibliografia Pdf
   Struktura chemiczna  

Nazwa handlowa   Nazwa handlowa     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abiplatin Afryka Południowa
Accocit Meksyk
Briplatin Japonia
Cisplatex Brazylia
Cisplatin Arabia Saudyjska, Australia, Austria, Belgia, Kanada
Cisplatina Brazylia
Cisplatine Belgia, Francja
Cisplatyl Arabia Saudyjska, Francja , Grecja, Turcja
Citoplatino Argentyna, Włochy
Citoplax Brazylia
Corsis Meksyk
Insel Brazylia
Neoplatin Hiszpania
Pamifect Indie
Placis Hiszpania, Turcja
Platamine Grecja, Maroko, Tunisie, Włochy
Platanovag Argentyna
Platiblastin Austria
Platidiam Polska, Węgry
Platinex Niemcy, Wielka Brytania, Włochy
Platinol Austria, Belgia, Dania, Finlandia, Grecja, Holandia, Luksemburg, Meksyk, Stany Zjednoczone Ameryki, Szwajcaria, Szwecja
Platistil Hiszpania
Platistine Belgia, Brazylia, Luksemburg
Platosin Belgia, Egipt, Grecja, Holandia, Japonia, Rumunia, Turcja, Wenezuela
Pronto Platamine Włochy
Zuridry Meksyk
Bibliografia   Injekcje   Bibliografia : Cisplatin  
Typ Publikacja
3 Czasopismo Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
53 Czasopismo Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD.
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
57 Czasopismo Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Czasopismo Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Czasopismo Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Czasopismo Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Czasopismo Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Czasopismo Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
147 Czasopismo Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV.
Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material.
Pharm World Sci 1993 ; 15: 34-36.
149 Czasopismo Rochard E, Barthes D, Courtois P.
Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs.
J Clin Pharm Ther 1992 ; 17: 315-318.
164 Czasopismo Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC.
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags.
J Clin Pharm Ther 1994 ; 19: 95-100.
169 Czasopismo Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244 Czasopismo Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Czasopismo Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Czasopismo Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Czasopismo Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
331 Czasopismo Marquardt ED.
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Am J Hosp Pharm 1988 ; 45: 2127.
334 Czasopismo Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Czasopismo Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
409 Czasopismo Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP.
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Am J Hosp Pharm 1987 ; 44: 124-130.
410 Czasopismo Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE.
Characterization of cisplatin degradation as affected by pH and light.
Am J Hosp Pharm 1991 ; 48: 1500-1506.
413 Czasopismo Stewart CF, Fleming RA.
Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
Am J Hosp Pharm 1990 ; 47: 1373-1377.
417 Czasopismo Stewart CF, Hampton EM.
Stability of cisplatin and etoposide in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 1400-1404.
492 Czasopismo Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
660 Czasopismo Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
742 Czasopismo Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF.
Stability of cisplatin in aqueous solution.
Am J Hosp Pharm 1979 ; 36: 38-43.
855 Czasopismo Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW.
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.
Cancer Chemother Pharmacol 1992 ; 29: 252-255.
872 Czasopismo Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F.
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions.
Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905 Czasopismo Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Czasopismo Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1080 Czasopismo La Folette JM, Arbus MH, Lauper RD.
Stability of cisplatin admixtures in polyvinyl chloride bags.
Am J Hosp Pharm 1985 ; 42: 2652.
1410 Czasopismo Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Czasopismo Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Czasopismo Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1729 Czasopismo Mittner A, Vincze Z, Jemnitz K.
Stability of cisplatin containing infusion.
Pharmazie 1998 ; 53: 490-492.
1925 Czasopismo Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1950 Czasopismo Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1953 Czasopismo Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Czasopismo Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247 Czasopismo Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Czasopismo Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3183 Czasopismo Sewell G
Physical and chemical stability of cisplatin infusions in PVC containers.
EJOP 2010 ; 4, 3: 11-13.
3474 Laboratorium Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3574 Laboratorium Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3578 Laboratorium Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3602 Laboratorium Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3670 Czasopismo Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
4084 Laboratorium Cisplatine - Résumé des caractéristiques du produits
Accord Health Care 2017
4137 Czasopismo Patel T, Sewell G.
Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare).
Newsletter Stabilis 2018 41;2-6
4589 Laboratorium Pemetrexed Mylan - Résumé des caractéristiques du produit
Mylan 2021

  Mentions Légales